PROCEPT BioRobotics Corporation (PRCT) Stock

PROCEPT BioRobotics Corporation is a pioneering surgical robotics company dedicated to advancing urology through innovative solutions. Specializing in minimally-invasive procedures, the company develops, manufactures, and markets the AquaBeam Robotic System, a state-of-the-art platform designed for precise urologic surgeries. Its flagship application focuses on treating benign prostatic hyperplasia (BPH), a common condition affecting males.

The AquaBeam Robotic System integrates cutting-edge image-guidance technology, enabling surgeons to perform Aquablation therapy with exceptional accuracy. This therapy addresses lower urinary tract symptoms associated with BPH, providing patients with effective relief and improved quality of life. As of December 31, 2021, PROCEPT BioRobotics Corporation boasted an install base of 130 AquaBeam Robotic Systems globally, including 78 systems deployed within the United States.

Founded in 2007 and headquartered in Redwood City, California, PROCEPT BioRobotics continues to lead the field of urologic surgery through ongoing innovation and strategic partnerships. The company's commitment to advancing surgical robotics underscores its mission to redefine treatment standards and enhance patient outcomes in urology.

With a strong foundation in technology and clinical expertise, PROCEPT BioRobotics Corporation remains at the forefront of transforming urologic care, addressing critical needs and expanding its global presence in the healthcare industry.